Trials / Terminated
TerminatedNCT00057447
Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Phase I/II Study of the Safety of Subcutaneous Interferon Gamma-1b Combined With Rituximab in Patients With Low Grade/Follicular Non-Hodgkin's Lymphoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- InterMune · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon Gamma-1b | 100 or 200 mcg, SQ, 3x per week |
| DRUG | Rituximab | 375 mg per square meters, IV, 1x per week |
Timeline
- Start date
- 2003-03-01
- Completion
- 2004-06-01
- First posted
- 2003-04-03
- Last updated
- 2007-11-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00057447. Inclusion in this directory is not an endorsement.